Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:08:25.063Z.
Calculation as of: 2026-10-06T17:08:25.063Z.
Quote observation: 2026-10-06T16:54:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fd4e67db9f72c8f7e350226876d0b852307266b6ff0bede5899e1be1bde0c950
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Polaryx Therapeutics, Inc. Common Stock
Market Cap
$104.68M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.79M
PS Ratio
N/A
TTM Avg
514.47
3Y Avg
387.29
5Y Avg
316.66
Market Cap
$106.68M
PS Ratio
3.41
TTM Avg
1.84
3Y Avg
1.24
5Y Avg
1.12
Market Cap
$107.44M
PS Ratio
N/A
TTM Avg
2.32
3Y Avg
2.32
5Y Avg
2.32
Market Cap
$108.05M
PS Ratio
N/A
TTM Avg
46.19
3Y Avg
46.23
5Y Avg
46.23
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $104.68M | N/A | N/A | N/A | N/A |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.79M | N/A | 514.47 | 387.29 | 316.66 |
| Definitive Healthcare Corp. (DH)vs › | $105.20M | 0.45 | 0.67 | 1.87 | 5.03 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.68M | 3.41 | 1.84 | 1.24 | 1.12 |
| The Joint Corp. (JYNT)vs › | $102.65M | 1.75 | 34.24 | 14.02 | 10.44 |
| Immunic, Inc. (IMUX)vs › | $107.34M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.44M | N/A | 2.32 | 2.32 | 2.32 |
| Outlook Therapeutics, Inc. (OTLK)vs › | $108.05M | N/A | 46.19 | 46.23 | 46.23 |
| OnKure Therapeutics, Inc. (OKUR)vs › | $101.24M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.20M | N/A | 119.38 | 60.79 | 244.46 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
